Work

Analisis Efektivitas Biaya Pada Pasien Sepsis Yang Diberikan Terapi Antibiotik Seftriakson Atau Meropenem Di Intensive Care Unit Rsud Berkah Pandeglang Periode 2022-2023

Year: 2025

Type: article

Abstract: Sepsis is a systemic infection commonly occurring in hospitals, which can lead to serious complications and even death if not treated promptly and effectively. Antibiotic therapy plays a crucial role in the success of sepsis treatment. However, inappropriate use of antibiotics can hinder treatment outcomes and directly impact hospitalization costs. This study aims to compare the cost-effectiveness of ceftriaxone and meropenem antibiotic treatments in sepsis patients at Berkah Pandeglang Hospital. The research utilized a retrospective data collection method, using secondary data from 2022-2023. Data were obtained from the medical records of sepsis patients hospitalized in the Intensive Care Unit (ICU). The sample consisted of 20 patients, with 11 receiving ceftriaxone and 9 receiving meropenem. The Average Cost-Effectiveness Ratio (ACER) for the ceftriaxone group was Rp. 124,470, while for the meropenem group it was Rp. 119,058. These results indicate that meropenem is more cost-effective than ceftriaxone in this study.

Source: Pharma xplore Jurnal Sains dan Ilmu Farmasi

DOI: 10.36805/jpx.v10i1.10076

Authors: Yusransyah Yusransyah, Cita Khalawatilah, Asti Yunia Rindarwati, Sofi Nurmay Stiani, Baha Udin

Institutions: Sekolah Tinggi Ilmu Kesehatan Salsabila Serang, Bandung Institute of Technology

Language: English

Topic: Sepsis Diagnosis and Treatment

Subfield: Epidemiology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: diamond

OpenAlex ID: W4412370953

FWCI:

Cites:

Cited by:

Related to: 10